Table 1 Characteristics of Studies and Participants
Figure captions
Figure 1 Flow chart of study selection
Figure 2 Overall survival (a), and progression-free survival (b), PD-L1 positive related overall survival (c), and PD-L1 negative related overall survival (d)Figure 3 HPV related overall survival (a), objective response rate (b), and HPV related disease control rate (c)Figure 4 Any grade (a) and grade ≥3 (b) adverse events of PD-1/PD-L1inhibitors alone groups Figure 5 Individual analyses of any grade adverse events of PD-1/PD-L1 inhibitors alone groupsFigure 6 Individual analyses of grade ≥3 adverse events of PD-1/PD-L1 inhibitors alone groups
Footnotes: PD-1: programmed death 1 receptor; PD-L1: programmed death-ligand1; HPV: human papillomavirus; ECOG: Eastern Cooperative Oncology Group. KEYNOTE-048 (1) represents the study involved PD-1/PD-L1 inhibitors alone groups versus control groups; KEYNOTE-048 (2) represents the study involved PD-1/PD-L1 inhibitors with conventional therapy groups versus control groups. REACH (1) represents the control group as standard of care (cisplatin); REACH (2) represents the control group as standard of care (cetuximab).
PD-L1 status was characterized by PD-L1 combined positive score (CPS) calculated by the percentage of tumor cells, lymphocytes, and macrophages in the amount of tumor cells (Burtness et al., 2019; Cohen et al., 2019). PD-L1 was positive when PD-L1 CPS ≥1, otherwise PD-L1 was negative.